{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:16:14Z","timestamp":1794255374026,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Older adults with HIV, particularly those\u2009\u2265\u200950 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in people with HIV (PWH)\u2009\u2265\u200950 years of age across treatment-na\u00efve and virologically suppressed cohorts over a long-term follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This post hoc analysis included participants\u2009\u2265\u200950 and &lt;\u200950 years of age from six phase 3 trials of B\/F\/TAF, comprising 2 treatment-na\u00efve studies and 4 virologically suppressed studies. Outcomes were assessed through Week 240 for the treatment-na\u00efve cohort and Week 48 for the virologically suppressed cohort. Key measures included virologic outcomes (HIV-1 RNA\u2009&lt;\u200950 or \u2265\u200950 copies\/mL), CD4 T-cell changes, adherence, metabolic and renal parameters, treatment-emergent adverse events, and treatment-emergent diabetes and hypertension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The treatment-na\u00efve cohort included 96 participants\u2009\u2265\u200950 years of age and 538 participants\u2009&lt;\u200950 years of age, while the virologically suppressed cohort included 450 participants\u2009\u2265\u200950 years of age and 640 participants\u2009&lt;\u200950 years of age. By Week 240, virologic suppression was achieved in 98.5% of treatment-na\u00efve participants\u2009\u2265\u200950 years of age and in 98.6% of those\u2009&lt;\u200950 years of age, as determined using missing\u2009=\u2009excluded analysis. By Week 48, virologic failure was 0.9% versus 1.4% in participants\u2009\u2265\u200950 years of age versus &lt;\u200950 years of age, respectively, and virologic suppression was maintained in 93.6% of virologically suppressed participants in both the \u2265\u200950 and &lt;\u200950 years of age groups, as assessed using the US Food and Drug Administration snapshot algorithm. Across age groups, the treatment-na\u00efve and virologically suppressed cohorts demonstrated comparable outcomes beyond viral load through Weeks 240 and 48, respectively, including CD4 T-cell changes, adherence rates of \u2265\u200995%, body weight, lipid profiles, renal function, bone health, treatment-emergent adverse events, and the incidence of treatment-emergent diabetes and hypertension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results highlight the durability, long-term efficacy, safety, and overall benefits of B\/F\/TAF in PWH\u2009\u2265\u200950 years of age.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-11476-3","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:42:21Z","timestamp":1755880941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of B\/F\/TAF in treatment-na\u00efve and virologically suppressed people with HIV\u2009\u2265\u200950 years of age: integrated analysis from six phase 3 clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Cissy M.","family":"Kityo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy N.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumi","family":"Gandhi-Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"4","key":"11476_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256\u201366.","journal-title":"HIV Med"},{"issue":"1","key":"11476_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12976-016-0047-0","volume":"14","author":"Y Xiao","year":"2017","unstructured":"Xiao Y, Sun X, Tang S, Zhou Y, Peng Z, Wu J, et al. Personalized life expectancy and treatment benefit index of antiretroviral therapy. Theor Biol Med Model. 2017;14(1):1.","journal-title":"Theor Biol Med Model"},{"key":"11476_CR3","unstructured":"UNAIDS. 2023 UNAIDS global AIDS update. https:\/\/thepath.unaids.org\/wp-content\/themes\/unaids2023\/assets\/files\/2023_report.pdf. Accessed 30 Jan 2025."},{"issue":"11","key":"11476_CR4","doi-asserted-by":"publisher","first-page":"e0207005","DOI":"10.1371\/journal.pone.0207005","volume":"13","author":"CS Autenrieth","year":"2018","unstructured":"Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000\u20132020. PLoS One. 2018;13(11):e0207005.","journal-title":"PLoS One"},{"issue":"2","key":"11476_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","volume":"7","author":"A Chawla","year":"2018","unstructured":"Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183\u201395.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"11476_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.idc.2019.04.005","volume":"33","author":"KM Erlandson","year":"2019","unstructured":"Erlandson KM, Karris MY. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019;33(3):769\u201386.","journal-title":"Infect Dis Clin North Am"},{"issue":"4","key":"11476_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1053\/j.semdp.2017.04.002","volume":"34","author":"E Kaplan-Lewis","year":"2017","unstructured":"Kaplan-Lewis E, Aberg JA, Lee M. Aging with HIV in the ART era. Semin Diagn Pathol. 2017;34(4):384\u201397.","journal-title":"Semin Diagn Pathol"},{"key":"11476_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042359","author":"RA Roomaney","year":"2022","unstructured":"Roomaney RA, van Wyk B, van Pillay- Wyk V. Aging with HIV: increased risk of HIV comorbidities in older adults. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph19042359.","journal-title":"Int J Environ Res Public Health"},{"key":"11476_CR9","doi-asserted-by":"publisher","unstructured":"Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, et al. Changes in atherosclerotic cardiovascular disease risk scores in a predominantly black cohort with HIV and associated comorbidities: a preliminary study. Cardiol Published Online August. 2024;6. https:\/\/doi.org\/10.1159\/000540526.","DOI":"10.1159\/000540526"},{"issue":"12","key":"11476_CR10","first-page":"1525","volume":"216","author":"J Gallant","year":"2017","unstructured":"Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection-a trend analysis. J Infect Dis. 2017;216(12):1525\u201333.","journal-title":"J Infect Dis"},{"issue":"12","key":"11476_CR11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1097\/QAD.0000000000003970","volume":"38","author":"MC Masters","year":"2024","unstructured":"Masters MC, Tassiopoulos K, Bao Y, Wu K, Koletar SL, Rubin LH, et al. Risk factors for progression from prediabetes to diabetes among older people with HIV. AIDS. 2024;38(12):1740\u20138.","journal-title":"AIDS"},{"issue":"11","key":"11476_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIRCRESAHA.124.323948","volume":"134","author":"K McCutcheon","year":"2024","unstructured":"McCutcheon K, Nqebelele U, Murray L, Thomas TS, Mpanya D, Tsabedze N. Cardiac and renal comorbidities in aging people living with HIV. Circ Res. 2024;134(11):1636\u201360.","journal-title":"Circ Res"},{"issue":"4","key":"11476_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/COH.0000000000000067","volume":"9","author":"GN Nadkarni","year":"2014","unstructured":"Nadkarni GN, Konstantinidis I, Wyatt CM. HIV and the aging kidney. Curr Opin HIV AIDS. 2014;9(4):340\u20135.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"11476_CR14","volume":"14","author":"G Schinas","year":"2024","unstructured":"Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K. Bone disease in HIV: need for early diagnosis and prevention. Life (Basel). 2024;14(4): 522.","journal-title":"Life (Basel)"},{"issue":"1","key":"11476_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-024-04989-x","volume":"24","author":"M Skelton","year":"2024","unstructured":"Skelton M, Callahan C, Levit M, Finn T, Kister K, Matsumura S, et al. Men with HIV have increased alveolar bone loss. BMC Oral Health. 2024;24(1): 1248.","journal-title":"BMC Oral Health"},{"issue":"10107","key":"11476_CR16","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and Tenofovir Alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372.","journal-title":"Lancet"},{"issue":"4","key":"11476_CR17","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","volume":"4","author":"PE Sax","year":"2017","unstructured":"Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Bictegravir versus dolutegravir, each with emtricitabine and Tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154\u201360.","journal-title":"Lancet HIV"},{"issue":"6","key":"11476_CR18","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","volume":"6","author":"DA Wohl","year":"2019","unstructured":"Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and Tenofovir Alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355\u201363.","journal-title":"Lancet HIV"},{"key":"11476_CR19","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"11476_CR20","doi-asserted-by":"publisher","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","volume":"6","author":"F Maggiolo","year":"2019","unstructured":"Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, et al. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing Tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and Tenofovir Alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019;6(10):e655\u201366.","journal-title":"Lancet HIV"},{"issue":"9","key":"11476_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","volume":"33","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455\u201365.","journal-title":"AIDS"},{"issue":"suppl 1","key":"11476_CR22","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/00002030-200418001-00004","volume":"18","author":"CH Hinkin","year":"2004","unstructured":"Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(suppl 1):S19\u201325.","journal-title":"AIDS"},{"issue":"10","key":"11476_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40266-013-0107-7","volume":"30","author":"L Ghidei","year":"2013","unstructured":"Ghidei L, Simone MJ, Salow MJ, Zimmerman KM, Paquin AM, Skarf LM, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging. 2013;30(10):809\u201319.","journal-title":"Drugs Aging"},{"issue":"1","key":"11476_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/QAD.0000000000001685","volume":"32","author":"KJ Siefried","year":"2018","unstructured":"Siefried KJ, Mao L, Cysique LA, Rule J, Giles ML, Smith DE, et al. Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS. 2018;32(1):35\u201348.","journal-title":"AIDS"},{"issue":"5","key":"11476_CR25","doi-asserted-by":"publisher","first-page":"e02533","DOI":"10.1128\/AAC.02533-18","volume":"63","author":"RK Acosta","year":"2019","unstructured":"Acosta RK, Willkom M, Martin R, Chang S, Wei X, Garner W, et al. Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks. Antimicrob Agents Chemother. 2019;63(5):e02533-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"11476_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/2325957415614642","volume":"15","author":"W Ombeni","year":"2016","unstructured":"Ombeni W, Kamuhabwa AR. Lipid profile in HIV-infected patients using first-line antiretroviral drugs. J Int Assoc Provid AIDS Care. 2016;15(2):164\u201371.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"1","key":"11476_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12879-023-08587-0","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Song X, Han Y, Qiu Z, Cao W, Li T. Risk factors and longitudinal changes of dyslipidemia among Chinese people living with HIV receiving antiretroviral therapy. BMC Infect Dis. 2023;23(1):598.","journal-title":"BMC Infect Dis"},{"issue":"9622","key":"11476_CR28","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"D:A:D study group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417\u201326.","journal-title":"Lancet"},{"key":"11476_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12916-016-0588-4","volume":"14","author":"CA Sabin","year":"2016","unstructured":"Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? a cohort collaboration. BMC Med. 2016;14:61.","journal-title":"BMC Med"},{"issue":"8","key":"11476_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"11476_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","volume":"9","author":"MT Lu","year":"2024","unstructured":"Lu MT, Ribaudo H, Foldyna B, Zanni MV, Mayrhofer T, Karady J, et al. Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial. JAMA Cardiol. 2024;9(4):323\u201334.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"11476_CR32","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","volume":"8","author":"O Ogbuagu","year":"2021","unstructured":"Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, et al. Long-term safety and efficacy of emtricitabine and Tenofovir Alafenamide vs emtricitabine and Tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021;8(7):e397\u2013407.","journal-title":"Lancet HIV"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11476-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11476-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:13:47Z","timestamp":1757416427000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11476-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11476"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11476-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki and approved by the following ethics committees: Commissie voor Medische Ethiek, Universitair Ziekenhuis Gent, Belgium; CPP Sud Mediterranee V, CHU de NICE - Hopital de CIMIEZ, France; Ethikkommission des Fachbereichs Medizin der Johann Wolfgang Goethe-Universit\u00e4t Frankfurt am Main, Germany; Comitato Etico, Istituto Nazionale per le Malattie Infettive \u201cLazzaro Spallanzani\u201d IRCCS, Italy; Comitato Etico, IRCCS Ospedale S. Raffaele di Milano, Italy; Comitato Etico della Provincia di Bergamo, ASST Papa Giovanni XXIII, Italy; CEIC Hospital Universitari de Bellvitge, Spain; National Research Ethics Service Committee London - Hampstead Research Ethics Committee, United Kingdom; Sunnybrook Research Ethics Board, Sunnybrook Health Sciences Centre, Canada; Ottawa Health Science Network Research Ethics Board, Canada; Centre for Applied Ethics\/MUHC Research Ethics Board, McGill University Health Centre, Canada; Advarra Institutional Review Board, United States; Prisma Health Institutional Review Board, United States; Institutional Review Board at Dallas, University of Texas Southwestern Medical Center, United States; Duke University Health System Institutional Review Board, United States; Bellberry Human Research Ethics Committee, Australia; St Vincent\u2019s Hospital Human Research Ethics Committee, Australia. Institutional review boards at each site granted ethical approval, and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CMK reports grants or contracts from Janssen. SKG reports grants or contracts from the National Institutes of Health and ViiV Healthcare; consulting fees from Gilead Sciences, Inc., and ViiV Healthcare. PNK reports grants or contracts from ViiV Healthcare, Gilead Science, Inc., Merck, and Theratechnologies; consulting fees from ViiV Healthcare, Gilead Sciences, Inc., and Merck; participation on a data safety monitoring board or advisory board from ViiV Healthcare, Gilead Sciences, Inc., and Merck; stock or stock options from Merck, Pfizer, Gilead Sciences, Inc., Johnson & Johnson, GSK, and Moderna. ARW, BG-P, HL, and JTH are employees and stockholders of Gilead Sciences, Inc. JKR reports grants or contracts from Gilead Sciences Inc.; consulting fees from AbbVie and Boehringer Ingelheim; payment or honoraria from Gilead Sciences Inc., Janssen, MSD, and ViiV Healthcare; participation on a data safety monitoring board or advisory board from Berlin Cures; other leadership or fiduciary role for EuroTESt.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1061"}}